NF1-PN Specialty Channel

NF1-PN

Specialty Channel

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Management of Adverse Events Associated With Selumetinib for Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

09/17/2024

Allison Casey ;

A panel of experts provided consensus recommendations on prevention, early detection, and management of adverse events potentially associated with selumetinib among pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas.

A panel of experts provided...

09/17/2024

Oncology

News

Hearing Loss Among Pediatric Patients with Neurofibromatosis Type 1

08/29/2024

Allison Casey ;

According to a review of audiometric data, the rate of hearing loss among patients with neurofibromatosis type 1 (NF1) compared to the general population was higher than expected.

According to a review of...

08/29/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology

News

Selumetinib Shows Efficacy, Safety Among Pediatric and Adult Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma

07/09/2024

Allison Casey ;

According to a phase 2 study, selumetinib demonstrated efficacy among both children and adults with NF1 and inoperable plexiform neurofibromas, and in other manifestations.

According to a phase 2 study,...

07/09/2024

Oncology

News

Study Findings Show Considerable Disease Burden of NF1-PN Among Affected Patients

07/01/2024

Janelle Bradley ;

Findings from the real-world CASSIOPEA study show the considerable disease burden of neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) highlighting the importance of effective treatments for this patient population.

Findings from the real-world...

07/01/2024

Oncology

News

Vinblastine/Methotrexate Fails to Demonstrate Activity for NF1-PN in Pediatric and Young-Adult Patients

07/01/2024

Janelle Bradley ;

Findings from a phase 2 study show vinblastine/methotrexate did not demonstrate activity for neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) in pediatric and young-adult patients, despite being well-tolerated.

Findings from a phase 2 study...

07/01/2024

Oncology

News

07/01/2024

Janelle Bradley ;

Study findings show neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) worsens adult patient and caregiver health-related quality of life vs that of the general population.

Study findings show...

07/01/2024

Oncology

News

Selumetinib for Managing NF1-PN in Pediatric Patients at Risk for Developing Tumor-Related Morbidity

07/01/2024

Janelle Bradley ;

Among pediatric patients with neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN), treatment with selumetinib resulted in significant shrinkage in PN without any clinically significant morbidity.

Among pediatric patients with...

07/01/2024

Oncology

Recent News

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial,...

11/12/2024

Oncology

News

Management of Adverse Events Associated With Selumetinib for Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

09/17/2024

Allison Casey ;

A panel of experts provided...

09/17/2024

Oncology

News

Hearing Loss Among Pediatric Patients with Neurofibromatosis Type 1

08/29/2024

Allison Casey ;

According to a review of audiometric data, the rate of hearing loss among patients with neurofibromatosis type 1 (NF1) compared to the general population was higher than expected.

According to a review of...

08/29/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the...

08/01/2024

Oncology

News

Selumetinib Shows Efficacy, Safety Among Pediatric and Adult Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma

07/09/2024

Allison Casey ;

According to a phase 2 study, selumetinib demonstrated efficacy among both children and adults with NF1 and inoperable plexiform neurofibromas, and in other manifestations.

According to a phase 2 study,...

07/09/2024

Oncology

News

Study Findings Show Considerable Disease Burden of NF1-PN Among Affected Patients

07/01/2024

Janelle Bradley ;

Findings from the real-world...

07/01/2024

Oncology

News

Vinblastine/Methotrexate Fails to Demonstrate Activity for NF1-PN in Pediatric and Young-Adult Patients

07/01/2024

Janelle Bradley ;

Findings from a phase 2 study...

07/01/2024

Oncology

News

07/01/2024

Janelle Bradley ;

Study findings show neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) worsens adult patient and caregiver health-related quality of life vs that of the general population.

Study findings show...

07/01/2024

Oncology

News

Selumetinib for Managing NF1-PN in Pediatric Patients at Risk for Developing Tumor-Related Morbidity

07/01/2024

Janelle Bradley ;

Among pediatric patients with...

07/01/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology